Academic Journal
View in EDS

The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Bibliographic Details
Title: The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Authors: Deniz Can Guven, Taha Koray Sahin, Enes Erul, Alessandro Rizzo, Angela Dalia Ricci, Sercan Aksoy, Suayib Yalcin
Source: Frontiers in Molecular Biosciences, Vol 9 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Biology (General)
Subject Terms: biomarker, cancer, immunotherapy, prognosis, albumin, Biology (General), QH301-705.5
More Details: Background: The albumin levels may potentially be used as a prognostic biomarker in patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close relationship with nutritional and inflammatory status. However, the available data is limited with heterogeneous patient cohorts, sample sizes and variable cut-offs. Therefore, we conducted a systematic review and meta-analysis to evaluate the association between survival outcomes and albumin levels in patients treated with ICIs.Methods: We conducted a systematic review using the PubMed, Web of Science, and Embase databases to filter the published studies up to 1 June 2022. The meta-analyses were performed with the generic inverse-variance method with a random-effects model due to the high degree of heterogeneity. The primary outcome measure was hazard ratio (HR) with 95% confidence intervals (CI). The study protocol was registered with the PROSPERO registry (Registration Number: CRD42022337746).Results: Thirty-six studies encompassing 8406 cancer patients with advanced disease were included in the meta-analyses. Almost half of the studies were conducted in NSCLC cohorts (n = 15), and 3.5 gr/dL was the most frequently used albumin cut-off in the included studies (n = 20). Patients with lower albumin levels had a significantly increased risk of death (HR: 1.65, 95% CI: 1.52–1.80, p < 0.0001) than patients with higher albumin levels. Subgroup analyses for study location, sample size, tumor type and albumin cut-off were demonstrated consistent results. Furthermore, in the subgroup analysis of eight studies using albumin levels as a continuous prognostic factor, every 1 gr/dL decrease in albumin levels was associated with significantly increased risk of death by a factor of 10% (HR: 1.10, 95% CI: 1.05–1.16, p = 0.0002). Similar to analyses with overall survival, the patients with lower albumin levels had an increased risk of progression or death compared to patients with higher albumin levels (HR: 1.76, 95% CI: 1.40–2.21, p < 0.001).Conclusion: The available evidence demonstrates that albumin levels may be a prognostic biomarker in advanced cancer patients treated with ICIs. Further research is needed to delineate the role of albumin levels in patients treated with ICIs in the adjuvant setting, as well as the possible benefit of therapeutic approaches to improve hypoalbuminemia.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2296-889X
Relation: https://www.frontiersin.org/articles/10.3389/fmolb.2022.1039121/full; https://doaj.org/toc/2296-889X
DOI: 10.3389/fmolb.2022.1039121
Access URL: https://doaj.org/article/3ae9093ba7964ef68f6b39871f995827
Accession Number: edsdoj.3ae9093ba7964ef68f6b39871f995827
Database: Directory of Open Access Journals
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=2296889X&ISBN=&volume=9&issue=&date=20221201&spage=&pages=&title=Frontiers in Molecular Biosciences&atitle=The%20association%20between%20albumin%20levels%20and%20survival%20in%20patients%20treated%20with%20immune%20checkpoint%20inhibitors%3A%20A%20systematic%20review%20and%20meta-analysis&aulast=Deniz%20Can%20Guven&id=DOI:10.3389/fmolb.2022.1039121
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/3ae9093ba7964ef68f6b39871f995827
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.3ae9093ba7964ef68f6b39871f995827
RelevancyScore: 953
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 953.493530273438
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Deniz+Can+Guven%22&quot;&gt;Deniz Can Guven&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Taha+Koray+Sahin%22&quot;&gt;Taha Koray Sahin&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Enes+Erul%22&quot;&gt;Enes Erul&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Alessandro+Rizzo%22&quot;&gt;Alessandro Rizzo&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Angela+Dalia+Ricci%22&quot;&gt;Angela Dalia Ricci&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sercan+Aksoy%22&quot;&gt;Sercan Aksoy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Suayib+Yalcin%22&quot;&gt;Suayib Yalcin&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Frontiers in Molecular Biosciences, Vol 9 (2022)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Frontiers Media S.A., 2022.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2022
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Biology (General)
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22biomarker%22&quot;&gt;biomarker&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22cancer%22&quot;&gt;cancer&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22immunotherapy%22&quot;&gt;immunotherapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22prognosis%22&quot;&gt;prognosis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22albumin%22&quot;&gt;albumin&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Biology+%28General%29%22&quot;&gt;Biology (General)&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22QH301-705%2E5%22&quot;&gt;QH301-705.5&lt;/searchLink&gt;
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Background: The albumin levels may potentially be used as a prognostic biomarker in patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close relationship with nutritional and inflammatory status. However, the available data is limited with heterogeneous patient cohorts, sample sizes and variable cut-offs. Therefore, we conducted a systematic review and meta-analysis to evaluate the association between survival outcomes and albumin levels in patients treated with ICIs.Methods: We conducted a systematic review using the PubMed, Web of Science, and Embase databases to filter the published studies up to 1 June 2022. The meta-analyses were performed with the generic inverse-variance method with a random-effects model due to the high degree of heterogeneity. The primary outcome measure was hazard ratio (HR) with 95% confidence intervals (CI). The study protocol was registered with the PROSPERO registry (Registration Number: CRD42022337746).Results: Thirty-six studies encompassing 8406 cancer patients with advanced disease were included in the meta-analyses. Almost half of the studies were conducted in NSCLC cohorts (n = 15), and 3.5 gr/dL was the most frequently used albumin cut-off in the included studies (n = 20). Patients with lower albumin levels had a significantly increased risk of death (HR: 1.65, 95% CI: 1.52–1.80, p &lt; 0.0001) than patients with higher albumin levels. Subgroup analyses for study location, sample size, tumor type and albumin cut-off were demonstrated consistent results. Furthermore, in the subgroup analysis of eight studies using albumin levels as a continuous prognostic factor, every 1 gr/dL decrease in albumin levels was associated with significantly increased risk of death by a factor of 10% (HR: 1.10, 95% CI: 1.05–1.16, p = 0.0002). Similar to analyses with overall survival, the patients with lower albumin levels had an increased risk of progression or death compared to patients with higher albumin levels (HR: 1.76, 95% CI: 1.40–2.21, p &lt; 0.001).Conclusion: The available evidence demonstrates that albumin levels may be a prognostic biomarker in advanced cancer patients treated with ICIs. Further research is needed to delineate the role of albumin levels in patients treated with ICIs in the adjuvant setting, as well as the possible benefit of therapeutic approaches to improve hypoalbuminemia.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 2296-889X
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://www.frontiersin.org/articles/10.3389/fmolb.2022.1039121/full; https://doaj.org/toc/2296-889X
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.3389/fmolb.2022.1039121
– Name: URL
  Label: Access URL
  Group: URL
  Data: &lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://doaj.org/article/3ae9093ba7964ef68f6b39871f995827&quot; linkWindow=&quot;_blank&quot;&gt;https://doaj.org/article/3ae9093ba7964ef68f6b39871f995827&lt;/link&gt;
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.3ae9093ba7964ef68f6b39871f995827
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.3ae9093ba7964ef68f6b39871f995827
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fmolb.2022.1039121
    Languages:
      – Text: English
    Subjects:
      – SubjectFull: biomarker
        Type: general
      – SubjectFull: cancer
        Type: general
      – SubjectFull: immunotherapy
        Type: general
      – SubjectFull: prognosis
        Type: general
      – SubjectFull: albumin
        Type: general
      – SubjectFull: Biology (General)
        Type: general
      – SubjectFull: QH301-705.5
        Type: general
    Titles:
      – TitleFull: The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Deniz Can Guven
      – PersonEntity:
          Name:
            NameFull: Taha Koray Sahin
      – PersonEntity:
          Name:
            NameFull: Enes Erul
      – PersonEntity:
          Name:
            NameFull: Alessandro Rizzo
      – PersonEntity:
          Name:
            NameFull: Angela Dalia Ricci
      – PersonEntity:
          Name:
            NameFull: Sercan Aksoy
      – PersonEntity:
          Name:
            NameFull: Suayib Yalcin
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2296889X
          Numbering:
            – Type: volume
              Value: 9
          Titles:
            – TitleFull: Frontiers in Molecular Biosciences
              Type: main
ResultId 1